Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience

1 Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377: 1919-29. doi: 10.1056/NEJMoa1709937Antonia SJ Villegas A Daniel D Vicente D Murakami S Hui R et al Durvalumab after chemoradiotherapy in stage III Non-Small-Cell Lung Cancer N Engl J Med 2017 377 1919 29 10.1056/NEJMoa1709937Open DOISearch in Google Scholar

2 Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342-50. doi: 10.1056/NEJMoa1809697Antonia SJ Villegas A Daniel D Vicente D Murakami S Hui R et al Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC N Engl J Med 2018 379 2342 50 10.1056/NEJMoa1809697Open DOISearch in Google Scholar

3 Hui R, Ozguroglu M, Villegas A, Daniel D, Vicente D, Murakami S, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol 2019; 20: 1670–80. doi: 10.1016/S1470-2045(19)30519-4Hui R Ozguroglu M Villegas A Daniel D Vicente D Murakami S et al Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study Lancet Oncol 2019 20 1670 80 10.1016/S1470-2045(19)30519-4Open DOISearch in Google Scholar

4 Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JH, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC Trial. J Thorac Oncol 2021; 16: 860-7. doi: 10.1016/j.jtho.2020.12.015Faivre-Finn C Vicente D Kurata T Planchard D Paz-Ares L Vansteenkiste JH et al Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC Trial J Thorac Oncol 2021 16 860 7 10.1016/j.jtho.2020.12.015Open DOISearch in Google Scholar

5 Yusuf D, Walton RN, Hurry M, Farrer D, Bebb DG, Cheung WY, et al. Population-based treatment patterns and outcomes for stage III non–small cell lung cancer patients. Am J Clin Oncol 2020; 43: 615-20. doi: 10.1097/COC.0000000000000716Yusuf D Walton RN Hurry M Farrer D Bebb DG Cheung WY et al Population-based treatment patterns and outcomes for stage III non–small cell lung cancer patients Am J Clin Oncol 2020 43 615 20 10.1097/COC.0000000000000716Open DOISearch in Google Scholar

6 Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017; 8: 1-20. doi: 10.5306/wjco.v8.i1.1Yoon SM Shaikh T Hallman M Therapeutic management options for stage III non-small cell lung cancer World J Clin Oncol 2017 8 1 20 10.5306/wjco.v8.i1.1Open DOISearch in Google Scholar

7 Brierly DJ, Gospodarowicz MK, Witekind C, editors. TNM classification of malignant tumours. 8th edition. Oxford: Wiley-Blackwell; 2017. p. 114-20.Brierly DJ Gospodarowicz MK Witekind C editors TNM classification of malignant tumours. 8th edition Oxford Wiley-Blackwell; 2017 p 114–20Search in Google Scholar

8 Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143-52. doi: 10.1016/S1470-2045(17)30074-8Seymour L Bogaerts J Perrone A Ford R Schwartz LH Mandrekar S et al iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics Lancet Oncol 2017 18 e143 52 10.1016/S1470-2045(17)30074-8Open DOISearch in Google Scholar

9 NIH. National Cancer Institute. DCTD Division of Cancer Treatment & Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. U.S. Department of Health and Human Services; 2017. [cited 2021 Jul 07]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdfNIH. National Cancer Institute. DCTD Division of Cancer Treatment & Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. U.S. Department of Health and Human Services; 2017 [cited 2021 Jul 07]. Available at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdfSearch in Google Scholar

10 Vrankar M, Zwitter M, Bavcar T, Milic A, Kovac V. Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial. Radiol Oncol 2014; 48: 369-80. doi: 10.2478/raon-2014-0026Vrankar M Zwitter M Bavcar T Milic A Kovac V Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial Radiol Oncol 2014 48 369 80 10.2478/raon-2014-0026423055725435850Open DOISearch in Google Scholar

11 Vrankar M, Stanic K. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Radiol Oncol 2018; 52: 281-8. doi: 10.2478/raon-2018-0009Vrankar M Stanic K Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy Radiol Oncol 2018 52 281 8 10.2478/raon-2018-0009613736730210037Open DOISearch in Google Scholar

12 Vrankar M, Kern I, Stanic K. Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy. Radiat Oncol 2020; 15: 247. doi: 10.1186/s13014-020-01696-zVrankar M Kern I Stanic K Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy Radiat Oncol 2020 15 247 10.1186/s13014-020-01696-z759426733121520Open DOISearch in Google Scholar

13 Taugner J, Käsmann L, Eze C, Tufman A, Reinmuth N, Duell T, et al. Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC leads to significant improvement of local-regional control and overall survival in the real-world setting. Cancers 2021; 13: 1613. doi: 10.3390/cancers13071613Taugner J Käsmann L Eze C Tufman A Reinmuth N Duell T et al Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC leads to significant improvement of local-regional control and overall survival in the real-world setting Cancers 2021 13 1613 10.3390/cancers13071613803742933807324Open DOISearch in Google Scholar

14 Offin M, Shaverdian N, Rimner A, Lobaugh S, Shepherd AF, Simone CB 2nd, et al. Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. Radiother Oncol 2020; 149: 205-11. doi: 10.1016/j.radonc.2020.04.047Offin M Shaverdian N Rimner A Lobaugh S Shepherd AF Simone CB 2nd, et al Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab Radiother Oncol 2020 149 205 11 10.1016/j.radonc.2020.04.047823942832361014Open DOISearch in Google Scholar

15 Desilets A, Blanc-Durand F, Lau S, Hakozaki T, Kitadai R, Malo J, et al. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. Eur J Cancer 2021; 142: 83-91. doi: 10.1016/j.ejca.2020.10.008Desilets A Blanc-Durand F Lau S Hakozaki T Kitadai R Malo J et al Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study Eur J Cancer 2021 142 83 91 10.1016/j.ejca.2020.10.00833242835Open DOISearch in Google Scholar

16 Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, et al. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer 2020; 150: 114-22. doi: 10.1016/j.lungcan.2020.10.006Faehling M Schumann C Christopoulos P Hoffknecht P Alt J Horn M et al Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP) Lung Cancer 2020 150 114 22 10.1016/j.lungcan.2020.10.00633126091Open DOISearch in Google Scholar

17 Faivre-Finn C, Spigel DR, Senan S, Langer C, Perez BA, Özgüroğlu M, et al. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab on unresectable Stage III NSCLC (PACIFIC). Lung Cancer 2021; 151: 30-8. doi: 10.1016/j.lungcan.2020.11.024Faivre-Finn C Spigel DR Senan S Langer C Perez BA Özgüroğlu M et al Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab on unresectable Stage III NSCLC (PACIFIC) Lung Cancer 2021 151 30 8 10.1016/j.lungcan.2020.11.02433285469Open DOISearch in Google Scholar

18 Jin G, Wang X, Xu C, Sun J, Yuan Z, Wang J, et al. Disparities in survival following surgery among patients with different histological types of N2-III non-small cell lung cancer: a Surveillance, Epidemiology and End Results (SEER) database analysis. Ann Transl Med 2020; 8: 1288. doi: 10.21037/atm-20-4357Jin G Wang X Xu C Sun J Yuan Z Wang J et al Disparities in survival following surgery among patients with different histological types of N2-III non-small cell lung cancer: a Surveillance, Epidemiology and End Results (SEER) database analysis Ann Transl Med 2020 8 1288 10.21037/atm-20-4357766189233209868Open DOISearch in Google Scholar

19 Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus K, Govindan R, et al. Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. J Thorac Oncol 2012; 7: 1479-84. doi: 10.1097/JTO.0b013e318267d032Morgensztern D Waqar S Subramanian J Gao F Trinkaus K Govindan R et al Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003 J Thorac Oncol 2012 7 1479 84 10.1097/JTO.0b013e318267d03222982648Open DOISearch in Google Scholar

20 Wang BY, Huang JY, Chen HC, Lin CH, Lin SH, Hung WH, et al. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. J Cancer Res Clin Oncol 2020; 146: 43–52. doi: 10.1007/s00432-019-03079-8Wang BY Huang JY Chen HC Lin CH Lin SH Hung WH et al The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients J Cancer Res Clin Oncol 2020 146 43 52 10.1007/s00432-019-03079-831705294Open DOISearch in Google Scholar

21 Attili I, Tarantino P, Passaro A, Stati V, Curigliano G, de Marinis F. Strategies to overcome resistance to immune checkpoint blockade in lung cancer. Lung Cancer 2021; 154: 151-60. doi: 10.1016/j.lungcan.2021.02.035Attili I Tarantino P Passaro A Stati V Curigliano G de Marinis F Strategies to overcome resistance to immune checkpoint blockade in lung cancer Lung Cancer 2021 154 151 60 10.1016/j.lungcan.2021.02.03533684660Open DOISearch in Google Scholar